These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
273 related articles for article (PubMed ID: 29070975)
1. Human Antibody Fusion Proteins/Antibody Drug Conjugates in Breast and Ovarian Cancer. Padayachee ER; Biteghe FAN; Malindi Z; Bauerschlag D; Barth S Transfus Med Hemother; 2017 Sep; 44(5):303-310. PubMed ID: 29070975 [TBL] [Abstract][Full Text] [Related]
2. Applications of SNAP-tag technology in skin cancer therapy. Padayachee ER; Adeola HA; Van Wyk JC; Nsole Biteghe FA; Chetty S; Khumalo NP; Barth S Health Sci Rep; 2019 Feb; 2(2):e103. PubMed ID: 30809593 [TBL] [Abstract][Full Text] [Related]
3. The efficient elimination of solid tumor cells by EGFR-specific and HER2-specific scFv-SNAP fusion proteins conjugated to benzylguanine-modified auristatin F. Woitok M; Klose D; Niesen J; Richter W; Abbas M; Stein C; Fendel R; Bialon M; Püttmann C; Fischer R; Barth S; Kolberg K Cancer Lett; 2016 Oct; 381(2):323-30. PubMed ID: 27502168 [TBL] [Abstract][Full Text] [Related]
4. Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells. Woitok M; Klose D; Di Fiore S; Richter W; Stein C; Gresch G; Grieger E; Barth S; Fischer R; Kolberg K; Niesen J Onco Targets Ther; 2017; 10():3313-3327. PubMed ID: 28740407 [TBL] [Abstract][Full Text] [Related]
5. CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate. Mungra N; Biteghe FAN; Malindi Z; Huysamen AM; Karaan M; Hardcastle NS; Bunjun R; Chetty S; Naran K; Lang D; Richter W; Hunter R; Barth S J Cancer Res Clin Oncol; 2023 Oct; 149(13):12203-12225. PubMed ID: 37432459 [TBL] [Abstract][Full Text] [Related]
7. Single-Domain Antibodies as Antibody-Drug Conjugates: From Promise to Practice-A Systematic Review. Medina Pérez VM; Baselga M; Schuhmacher AJ Cancers (Basel); 2024 Jul; 16(15):. PubMed ID: 39123409 [TBL] [Abstract][Full Text] [Related]
8. EpCAM- and EGFR-Specific Antibody Drug Conjugates for Triple-Negative Breast Cancer Treatment. Zhang C; Sheng W; Al-Rawe M; Mohiuddin TM; Niebert M; Zeppernick F; Meihold-Heerlein I; Hussain AF Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682800 [TBL] [Abstract][Full Text] [Related]
9. SNAP-tag technology mediates site specific conjugation of antibody fragments with a photosensitizer and improves target specific phototoxicity in tumor cells. Hussain AF; Kampmeier F; von Felbert V; Merk HF; Tur MK; Barth S Bioconjug Chem; 2011 Dec; 22(12):2487-95. PubMed ID: 21995499 [TBL] [Abstract][Full Text] [Related]
10. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas. Zhang L; Fang Y; Kopeček J; Yang J Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824 [TBL] [Abstract][Full Text] [Related]
11. Detection and Specific Elimination of EGFR Bauerschlag D; Meinhold-Heerlein I; Maass N; Bleilevens A; Bräutigam K; Al Rawashdeh W; Di Fiore S; Haugg AM; Gremse F; Steitz J; Fischer R; Stickeler E; Barth S; Hussain AF Pharm Res; 2017 Apr; 34(4):696-703. PubMed ID: 28074431 [TBL] [Abstract][Full Text] [Related]
12. SNAP-Tag Technology: A Useful Tool To Determine Affinity Constants and Other Functional Parameters of Novel Antibody Fragments. Niesen J; Sack M; Seidel M; Fendel R; Barth S; Fischer R; Stein C Bioconjug Chem; 2016 Aug; 27(8):1931-41. PubMed ID: 27391930 [TBL] [Abstract][Full Text] [Related]
13. Therapeutic efficacy of a novel humanized antibody-drug conjugate recognizing plexin-semaphorin-integrin domain in the RON receptor for targeted cancer therapy. Tong XM; Feng L; Suthe SR; Weng TH; Hu CY; Liu YZ; Wu ZG; Wang MH; Yao HP J Immunother Cancer; 2019 Sep; 7(1):250. PubMed ID: 31519211 [TBL] [Abstract][Full Text] [Related]
15. Recent Advances in Antibody-Drug Conjugates for Breast Cancer Treatment. Deng S; Lin Z; Li W Curr Med Chem; 2017; 24(23):2505-2527. PubMed ID: 28554322 [TBL] [Abstract][Full Text] [Related]
16. Sortase Enzyme-Mediated Generation of Site-Specifically Conjugated Antibody Drug Conjugates with High In Vitro and In Vivo Potency. Beerli RR; Hell T; Merkel AS; Grawunder U PLoS One; 2015; 10(7):e0131177. PubMed ID: 26132162 [TBL] [Abstract][Full Text] [Related]
17. Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer. Knutson S; Raja E; Bomgarden R; Nlend M; Chen A; Kalyanasundaram R; Desai S PLoS One; 2016; 11(6):e0157762. PubMed ID: 27336622 [TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer. Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298 [TBL] [Abstract][Full Text] [Related]
20. An enzymatic deconjugation method for the analysis of small molecule active drugs on antibody-drug conjugates. Li Y; Gu C; Gruenhagen J; Yehl P; Chetwyn NP; Medley CD MAbs; 2016; 8(4):698-705. PubMed ID: 26891281 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]